Compare Smith & Nephew plc (SNN) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Smith & Nephew plc trades at $30.45 (market cap $12.64B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.58. The key difference: Smith & Nephew plc pays a 2.57% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none. Which is the better fit depends on your goals.
| SNN | YMAG | |
|---|---|---|
Market Cap | $12.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $38.70 | $15.98 |
52-Week Low | $28.73 | $11.00 |
Enterprise Value | $15.41B | — |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
YMAG trades at $11.63, up 0.17% with a bearish technical signal from moving averages. The ETF provides weekly distributions, recently ranging from $0.07 to $0.40 per share, targeting income through covered calls on Magnificent Seven stocks. Key financial ratios are unavailable, limiting fundamental assessment. Recent news highlights distribution announcements and strategy discussions amid mixed sentiment regarding its performance versus peers.
Outlook hinges on volatility monetization via options, offering high yield but facing NAV decay risks. Investment appeal lies in income generation during range-bound markets, though underperformance in rising equity environments and high expenses pose challenges. Risks include dependency on underlying stock volatility and competitive ETF pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
